New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

From Twinlab: Breakthrough News on Weight Loss

Breakthrough News on Weight Loss

Stock up on Ripped Fuel, Diet Fuel, & Metabolift – Clinically Proven, Ephedra-free, Formulas Containing Thermogenic Ingredients to Aid in Weight Loss & Increased Energy Levels

HAUPPAUGE, NY (February 26, 2003), Twin Laboratories Inc. (Twinlab), a leading manufacturer of vitamins, minerals and nutritional supplements, would like to alert retailers of a possible increase in demand for Ephedra-free products as well as those that contain Green Tea Extract.

According to IMS Health Global Services, almost 55% of all adults in the United States were found to be overweight in 2000, and of these adults, more than 22% were obese. Other sources suggest that approximately $30 billion is spent each year on weight loss remedies in the United States including dietary foods and diet-related products and services. In addition, a National survey conducted by the Calorie Control Council in 2000 reported that 51 million people in the United States are on some form of diet.

Several reports regarding Green Tea Extract and its potential link to increased metabolism and weight loss have emerged as a result of clinical studies, including one published by the American Journal of Clinical Nutrition, which indicated that Green Tea Extract not only reduced body weight, but also significantly increased 24-hour energy expenditure. The authors of this study also concluded that 50 mg of Green Tea Extract (three times per day) has thermogenic properties that promote fat oxidation beyond that explained by the caffeine content alone.

Leading the way in the research and development of clinically tested, diet-centric formulas, Twinlab recently introduced its newly patented Ephedra-free formulas…Ripped Fuelâ, Diet Fuelâ, and Metaboliftâ that contain significant amounts of Green Tea and other natural fat fighting ingredients, offering customers a more natural, alternative way to shed unwanted pounds.

Twinlab’s Ripped Fuelâ, Diet Fuelâ, and Metaboliftâ are uniquely formulated, clinically tested products designed specifically to meet the individual needs of consumers. Ripped Fuelâ is geared toward athletic males age 18-34, looking to reduce fat and promote lean muscle mass. Twinlab’s Diet Fuelâ is designed for active females age 18-39 who desire increased definition and tone. Metaboliftâ products cater to less active women aged 25-49 years old who are looking for a fat fighting catalyst and increased metabolism. Ripped Fuelâ, Diet Fuelâ and Metaboliftâ contain a proprietary, all natural, herbal blend of thermogenic and metabolic ingredients including Guarana Seed Extract, Citrus Aurantium Fruit Extract, Green Tea Extract, Ginger Root Extract, Cayenne Fruit, among others.

Twinlab, in an effort to provide superior customer care, will endeavor to foster its retailer relationships through continued communications of relevant developments in the field of health, wellness, and nutrition.

Twinlab Corporation, headquartered in Hauppauge, N.Y., is a leading manufacturer and marketer of premium, science-based, nutritional supplements, including a complete line of vitamins, minerals, nutraceuticals, herbs and sports nutrition products. Twinlab attributes its title as “Number One Brand” in customer satisfaction to its 30+ years experience in producing products with the highest standards and quality of ingredients. Twinlab remains committed to providing consumers with optimal products that promote maximum health and wellness.

For more information on Twinlab and its products please contact your Sales Associate or Consumer Affairs at (800) 645-5626, or visit us on the World Wide Web at

Safe Harbor

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company’s financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: (i) the impact of competitive products; (ii) changes in law and regulations; (iii) adequacy and availability of insurance coverage; (iv) limitations on future financing; (v) increases in the cost of borrowings and unavailability of debt or equity capital; (vi) the effect of adverse publicity regarding nutritional supplements; (vii) uncertainties relating to acquisitions; (viii) the inability of the Company to gain and/or hold market share; (ix) exposure to and expense of resolving and defending product liability claims and other litigation; (x) consumer acceptance of the Company’s products; (xi) managing and maintaining growth; (xii) customer demands; (xiii) the inability to integrate and consolidate its manufacturing and distribution facilities and achieve cost savings and operational efficiencies; (xiv) dependence on individual products; (xv) dependence on individual customers, (xvi) market and industry conditions including pricing, demand for products, levels of trade inventories and raw materials availability, (xvii) the success of product development and new product introductions into the marketplace including the Company’s line of ephedra-free products; (xviii) lack of available product liability insurance for ephedra-containing products; (xix) slow or negative growth in the nutritional supplement industry; (xx) the departure of key members of management; (xxi) the absence of clinical trials for many of the Company’s products; (xxii) the ability of the Company to efficiently manufacture its products; as well as other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, copies of which are available upon request from the Company’s investor relations department.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.